Regeneron Pharmaceuticals (REGN) Stock Forecast & Price Target

Regeneron Pharmaceuticals is a fully integrated biopharmaceutical company with a strong pipeline of both commercialized and investigational products targeting multiple diseases. Despite the recent setback in the Phase III trial for mPFS, the company still maintains a strong position in the market with its marketed products, partnerships and collaborations, and a diverse pipeline. Its strong financials, including a profitable net income and a steady increase in revenue, make it a promising investment opportunity for the future.

Regeneron Pharmaceuticals is facing a negative outlook due to the recent failure of its LAG-3 inhibitor program in 1L melanoma, which missed its primary endpoint of PFS compared to pembrolizumab. This setback raises questions about the viability of the LAG-3 franchise's near-term prospects, especially in light of the recent discontinuation of their 1L NSCLC program. Along with the decrease in projected peak sales for the program, this has led to a lowering of their price target to $855 and a reduction in their probability of success from 50% to 15% for this program. The company also has a heavy reliance on its I&I franchises Eylea and Dupixent, and while these have shown real-world efficacy and safety, the recent failure of a key pipeline program in oncology raises questions about the long-term growth potential of the company.